Videos
Carlos L. Arteaga, MD, discusses the use of capecitabine after neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Kris Patel, MD, discusses the real-world data for treatment with ibrutinib in patients with relapsed/refractory mantle cell lymphoma as compared to clinical trials.
Treatment for Relapsed Chronic Lymphocytic Leukemia
Joaquim Bellmunt, MD, PhD, shares his recommendation in how to manage the side effects of immunotherapy as a monotherapy, particularly PD-1/PD-L1, in patients with bladder cancer.
Classical Hodgkin Lymphoma: Is There a Cure?
Unresectable HCC with a History of Hepatitis C Virus
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term Outcomes Offer Reassurance on Quadruplet Use in Transplant-Ineligible NDMM
2
FDA Approves Expanded Automated PD-L1 Diagnostic Testing Across 4 Solid Tumor Types
3
Velzatinib Aims For Future Direct Comparison With Imatinib in GIST
4
Allostatic Load Emerges as a Risk Marker for Early-Onset Cancer
5